Participated · Series A · May 2026

Ember LifeSciences develops reusable, modular cold-chain shipping platforms, including the flagship Ember Cube and the newly commercially available Ember Cube 2, which features real-time monitoring and cloud-based tracking. The Ember Cube 2 has received design recognition such as a Red Dot “Best of the Best,” and the company’s products have been cited by TIME and Fast Company. Ember’s customer base includes major pharmaceutical distributors and pharmacies such as CVS Health, Cardinal Health, Chartwell and USADA. The company originated as an offshoot of Ember Technologies, the maker of a temperature-control mug that has exceeded half a billion dollars in total sales. Ember says it will use recent strategic investments to scale its logistics platform rapidly and expand its global footprint.

Participated · Series B · Nov 2025

AAVantgarde Bio is advancing best-in-class AAV gene therapies aimed at treating severe inherited retinal diseases (IRDs) that currently have no approved therapies. Its lead candidate, AAVB-039, is being evaluated in the CELESTE study to address Stargardt disease caused by ABCA4 mutations, alongside the >100-patient STELLA natural history study. A second program, AAVB-081, is in a Phase 1/2 LUCE trial for retinitis pigmentosa secondary to Usher syndrome type 1B arising from MYO7A mutations. Led by CEO Dr. Natalia Misciattelli, the company plans to use newly secured capital to achieve clinical proof-of-concept for both programs. The pipeline positions AAVantgarde to enter mid-stage development in two large, unmet IRD markets. Financially, the company has just closed a substantial $141 million Series B round to fund these milestones, underscoring strong investor confidence in its platform. No revenue or patient adoption metrics have yet been disclosed, consistent with its clinical-stage status.

Participated · Series B · Oct 2025

Cartography Biosciences develops antibody-based cancer therapies by integrating large-scale single-cell datasets with computational biology through its ATLAS and SUMMIT discovery platforms. The company aggregates petabyte-scale proprietary data from healthy tissues and tumor profiles and applies machine learning and AI to identify tumor-restricted antigens and antigen combinations. Its platform supports the design of logic-gated and highly selective antibody therapeutics aimed at improving specificity and therapeutic index. Cartography is advancing a pipeline of oncology programs with its lead candidate, CBI-1214, a T-cell engager for colorectal cancer that entered clinical testing in early 2026 and is currently enrolling patients in a Phase 1 trial. The company stated that the strategic investment from Samsung Ventures will help accelerate its oncology programs and expand its drug discovery capabilities.

Participated · Series B · Sep 2025

Formed in 2021 through the merger of Honeywell Quantum Solutions and Cambridge Quantum, Quantinuum provides end-to-end quantum computing products and services. The company sells hardware and software, developer tools, and applications—its platform includes InQuanto, a tool for computational chemistry. Quantinuum is preparing to launch Helios, a next-generation quantum system intended to advance performance and move toward universal fault-tolerant quantum computing. The firm is expanding its global footprint and has announced partnerships and collaborations to explore hybrid and scalable quantum-classical models. Notable collaborations include work with NVIDIA at the Accelerated Quantum Research Center in Boston and partnerships with RIKEN, SoftBank Corp., Infineon Technologies, and the STFC Hartree Centre. Quantinuum is also expanding regionally with activity in New Mexico, Qatar (including a role in a $1 billion national initiative), and Singapore. Quantinuum is an integrated quantum computing company that develops quantum hardware and advanced software solutions to drive applications in materials discovery, cybersecurity, and next‑generation quantum AI. Led by CEO Rajeeb Hazra and based in Broomfield, Colorado, the company supplies technologies to firms including Airbus, BMW Group, Honeywell, HSBC, JPMorgan Chase, Mitsui and Thales. Quantinuum employs almost 500 people, including over 370 scientists and engineers. The company closed a $300m equity funding round at a $5 billion pre‑money valuation, bringing total capital raised since inception to approximately $625m. The round was anchored by strategic partner JPMorgan Chase, with participation from Mitsui & Co., Amgen, and Honeywell, which remains Quantinuum’s majority shareholder. Quantinuum intends to use the proceeds to accelerate the path toward universal fault‑tolerant quantum computers and to extend its software offering to enhance commercial applicability.

Participated · Series B · Aug 2025

Strand Therapeutics is developing programmable mRNA-based therapeutics that combine self-replicating and circular RNA modalities with genetically programmed logic circuits to enable precise, controlled payload delivery. Its platform is designed to localize and durably express therapeutic payloads, including IL-12, to reprogram the tumor microenvironment and stimulate systemic anti-tumor immunity. The lead program, STX-001, is a self-replicating mRNA encoding IL-12 that is in a Phase 1/2 clinical trial (IND cleared December 2023) and presented early human data at the 2025 ASCO Annual Meeting showing multiple RECIST responses, complete responses, prolonged disease stabilization, and a favorable safety profile. Strand also presented preclinical data for STX-003, a first-in-class systemically administrable, tumor-targeting mRNA therapy programmed to avoid off-target delivery including liver avoidance, at AACR and ASGCT. The company emphasizes a computational design engine and modular platform intended to expand into immuno-oncology, cell therapy, autoimmune diseases, and other indications, and to enable partnerships and licensing opportunities. Strand Therapeutics engineers programmable, long-acting mRNA therapeutics delivered in nanoparticles to control the location, timing, intensity, and duration of protein expression in patients. Its platform programs genetic logic circuits so mRNA senses microRNA signatures and restricts expression to target cells, aiming for improved efficacy and safety versus first-generation mRNA. The company is developing a pipeline of multifunctional mRNA candidates, including a lead programmable mRNA therapy for solid tumor immuno-oncology. Strand plans to advance that lead candidate into Phase 1 clinical trials next year and to further develop a systemic delivery mechanism to target tumor sites and immune cells. The company will expand its biology, bioengineering, bioinformatics, manufacturing, automation, and G&A teams to support clinical and delivery development. Strand is headquartered in Boston and has announced a Series A financing totaling $97 million to support these efforts. Strand Therapeutics develops programmable, long-acting self-replicating mRNA therapeutics designed to enable precise control of location, timing, intensity, and duration of therapeutic activity. Its platform combines self-replicating mRNAs with genetically programmed logic circuits that sense and classify cell-type expression signatures to deliver multi-functional treatments in a single mRNA drug. The company’s initial focus is cancer immunotherapy, with plans to begin clinical trials of its first candidate in 2022 and ambitions to address solid tumors and hematological malignancies. Strand is also developing programmable mRNA for generation of cell therapies intended to be re-doseable and off-the-shelf to expand patient access. The company has a licensing collaboration with BeiGene to develop and commercialize its multi-functional mRNA technology for solid tumor immuno-oncology. Financially, Strand announced an oversubscribed $52M Series A and has raised $66M in total to date. Strand Therapeutics is an early-stage biotechnology company building programmable, “smart” mRNA therapeutics using synthetic biology innovations developed at MIT. The company says it created a bespoke programming language to enable mRNA therapies that can make sophisticated decisions and dynamically respond to their microenvironment. Scientific co-founders include MIT professors Ron Weiss and Darrell J. Irvine; operational co-founders are Jacob Becraft (CEO) and Tasuku Kitada (President). Strand is initially targeting immuno-oncology and plans to extend into other disease indications as the platform matures. The company will use its latest financing to hire at its Cambridge, Massachusetts headquarters, grow its pipeline of engineered gene therapies, and further develop its synthetic biology platform. Strand is a resident company of Johnson & Johnson Innovation, JLABS.